Simulations Plus (NASDAQ:SLP) Updates FY25 Earnings Guidance

Simulations Plus (NASDAQ:SLP) updated its FY25 earnings guidance on Wednesday. The company provided earnings per share guidance of $1.07 to $1.20 for the period, compared to the consensus earnings per share estimate of $0.63. The company issued revenue guidance of $90 million to $93 million, compared to the consensus revenue estimate of $91.76 million. Simulations Plus also updated its FY 2025 guidance to 1.070-1.200 EPS.

Analyst Ratings Changes

Several research firms have weighed in on SLP. KeyCorp began coverage on Simulations Plus in a report on Monday, July 29th. They issued an “overweight” rating and a $47.00 target price on the stock. JMP Securities initiated coverage on shares of Simulations Plus in a report on Tuesday, July 16th. They set a “market perform” rating for the company. BTIG Research reduced their price target on shares of Simulations Plus from $60.00 to $50.00 and set a “buy” rating on the stock in a report on Thursday. William Blair reissued an “outperform” rating on shares of Simulations Plus in a research note on Thursday. Finally, Craig Hallum reaffirmed a “buy” rating and issued a $56.00 target price on shares of Simulations Plus in a research note on Wednesday, July 3rd. One equities research analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. According to data from MarketBeat, Simulations Plus presently has a consensus rating of “Moderate Buy” and an average target price of $54.50.

Simulations Plus Price Performance

Shares of NASDAQ SLP opened at $30.68 on Friday. Simulations Plus has a 12 month low of $29.37 and a 12 month high of $51.22. The company has a 50-day simple moving average of $33.08 and a 200-day simple moving average of $40.63. The company has a market cap of $613.91 million, a PE ratio of 63.92 and a beta of 0.69.

Simulations Plus (NASDAQ:SLP) last issued its quarterly earnings results on Wednesday, October 23rd. The technology company reported $0.06 earnings per share for the quarter, topping analysts’ consensus estimates of $0.04 by $0.02. Simulations Plus had a return on equity of 7.80% and a net margin of 14.36%. The company had revenue of $18.70 million for the quarter, compared to analyst estimates of $19.73 million. During the same quarter in the prior year, the company posted $0.18 EPS. The business’s revenue for the quarter was up 19.9% compared to the same quarter last year. On average, analysts anticipate that Simulations Plus will post 0.54 EPS for the current year.

Insider Buying and Selling at Simulations Plus

In related news, Director Walter S. Woltosz sold 20,000 shares of the firm’s stock in a transaction that occurred on Tuesday, September 3rd. The shares were sold at an average price of $35.18, for a total value of $703,600.00. Following the sale, the director now directly owns 3,501,592 shares of the company’s stock, valued at approximately $123,186,006.56. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders sold 60,750 shares of company stock worth $2,145,055 in the last 90 days. 20.90% of the stock is owned by company insiders.

About Simulations Plus

Simulations Plus, Inc develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through two segments, Software and Services. It offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products.